ReviewResearch and practice in thrombosis and haemostasis2026
Von Willebrand disease: A century of progress.
Review in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One hundred years after the initial description of von Willebrand disease, originally referred to as pseudohemophilia, this article is a tribute to Dr Erik von Willebrand and a testament to the progress in our understanding of von Willebrand factor. Main focuses have been on structure and hemostatic function, as well as the advancements in the diagnosis, genetics, and management of von Willebrand disease. Insightful early observations led to the discovery of the main VWF ligands and interaction domains and the molecular mechanisms controlling these associations in the context of hemostasis. Reflecting these intricate mechanisms, the genetics and diagnosis of von Willebrand disease remain challenging, especially for the mild, quantitative deficiencies. Treatment developments and innovations have historically progressed quite slowly and in the shadow of hemophilia. However, recent patient-centered studies underscoring unmet clinical needs have catalyzed a dynamic and rapidly evolving effort to improve patient care and clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.